ES2548442T3 - Reovirus que tienen secuencias modificadas - Google Patents

Reovirus que tienen secuencias modificadas Download PDF

Info

Publication number
ES2548442T3
ES2548442T3 ES08733587.3T ES08733587T ES2548442T3 ES 2548442 T3 ES2548442 T3 ES 2548442T3 ES 08733587 T ES08733587 T ES 08733587T ES 2548442 T3 ES2548442 T3 ES 2548442T3
Authority
ES
Spain
Prior art keywords
residue
leu
seq
val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08733587.3T
Other languages
English (en)
Inventor
Matthew C. Coffey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolytics Biotech Inc
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39758956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2548442(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of ES2548442T3 publication Critical patent/ES2548442T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un reovirus de tipo 3 modificado que comprende: un polipéptido lambda-3 que tiene las siguientes modificaciones de aminoácidos: una Leu en el residuo 979; una Val en el residuo 214, una Ala en el residuo 267, una Thr en el residuo 557, una Lys en el residuo 755, una Met en el residuo 756, una Pro en el residuo 926, una Pro en el residuo 963, una Arg en el residuo 1045, y una Val en el residuo 1071, contados con relación a SEQ ID NO: 23 (Registro de GenBank No. M24734.1).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
E08733587
28-09-2015
cosecha a granel. La suspensión celular combinada restante se transfirió a tubos cónicos y se centrifugó a ∼3000 rpm durante 15 minutos. Las células se resuspendieron luego con 400 mL de medio clarificado condicionado y la suspensión celular concentrada se congeló repentinamente en un baño de hielo seco de alcohol tres veces para lisar las células y luego se envasaron en crioviales estériles, etiquetados para uso en reacciones de secuenciación.
5 Ambas cepas de ARN fueron secuenciadas desde ambas direcciones y la secuencia de cada uno de los 10 segmentos genómicos se ensambló a partir de cóntigos que se solapan. La secuencia ensamblada de cada segmento genómico usada en una búsqueda BLAST (Basic Local Alignment Search Tool) de la base de datos de NCBI (ncbi.nlm.nih.gov en la World Wide Web). Se examinaron alineamientos con tres o cuatro secuencias diferentes de reovirus en la base de datos de NCBI y se usó el alineamiento que tenía la cantidad más alta de
10 homología para análisis posteriores. Los polimorfismos o modificaciones comparados con otras secuencias reportadas se muestran en la tabla 1. Aquellas modificaciones que son únicas para la cepa de reovirus seleccionada se indican con un asterisco en la tabla 1.
Tabla 1. Modificaciones Identificadas
Segmento Genómico
Posición (nucleótido; aminoácido) Secuencia publicada (nucleótido; aminoácido) Polimorfismo novedoso (nucleótido; aminoácido)
S1
Registro GenBank No. M10262.1 SEQ ID NO:1
499; 163
A;Thr T; Ser
S3
Registro GenBank No. X01627.1 SEQ ID NO:3
1057; 344
T; Leu C; Leu
S4
Registro GenBank No. K02739 SEQ ID NO:4
*
74; 14 G;Leu A; Leu
*
624; 198 G; Glu A;Lys
719; 229
G; Glu T; Asp
M1
Registro GenBank No. AF461684.1 SEQ ID NO:5
1129; 372
G; Met T; Ile
*
1595; 528 G; Ala T; Ser
M2
Registro GenBank No. M20161.1 SEQ ID NO:6
*
248; 73 A; Glu C; Asp
302; 91
G; Ala C; Ala
303; 92
C; Leu T; Leu
305; 92
T; Leu G; Leu
709-10; 227
CG; Thr GC; Ser
1173; 382
T; Leu C; Leu
L1
Registro GenBank No. M24734.1 SEQ ID NO:8
*
660; 214 A; Val T; Val
*
817; 267 T; Ser G; Ala
*
1687; 557 C; Pro A; Thr
*
2283; 755 C; Asn G; Lys
*
2284-6; 756 GAT; Asp ATG; Met
*
2794; 926 A; Thr C; Pro
*
2905; 963 T; Ser C; Pro
*
2953; 979 A; Met C; Leu
*
3153,1045 C; Ser A; Arg
*
3231; 1071 T; Val G; Val
L2
Registro GenBank No. J03488.1 SEQ ID NO:9
1838-40; 609
TTT; Phe GGG; Gly
3703; 1230
A; Leu G; Leu
10

Claims (1)

  1. imagen1
    imagen2
ES08733587.3T 2007-03-12 2008-03-11 Reovirus que tienen secuencias modificadas Active ES2548442T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89442507P 2007-03-12 2007-03-12
US894425P 2007-03-12
US98956807P 2007-11-21 2007-11-21
US989568P 2007-11-21
PCT/CA2008/000483 WO2008110004A1 (en) 2007-03-12 2008-03-11 Reoviruses having modified sequences

Publications (1)

Publication Number Publication Date
ES2548442T3 true ES2548442T3 (es) 2015-10-16

Family

ID=39758956

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08733587.3T Active ES2548442T3 (es) 2007-03-12 2008-03-11 Reovirus que tienen secuencias modificadas

Country Status (17)

Country Link
US (5) US7803385B2 (es)
EP (2) EP2132315B1 (es)
JP (1) JP5577103B2 (es)
KR (1) KR101647843B1 (es)
CN (1) CN103710359A (es)
AR (1) AR066395A1 (es)
AU (1) AU2008226291B2 (es)
CA (1) CA2678721C (es)
DK (1) DK2132315T3 (es)
ES (1) ES2548442T3 (es)
HK (1) HK1132761A1 (es)
IL (4) IL200353A (es)
MX (2) MX2009009598A (es)
SG (1) SG191602A1 (es)
TW (1) TW200904979A (es)
WO (1) WO2008110004A1 (es)
ZA (1) ZA200905951B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
ES2548442T3 (es) 2007-03-12 2015-10-16 Oncolytics Biotech Inc. Reovirus que tienen secuencias modificadas
US20100247622A1 (en) * 2007-10-22 2010-09-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
CA2723587C (en) * 2008-05-27 2017-09-26 Oncolytics Biotech Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
AU2009253682B2 (en) * 2008-05-27 2015-09-17 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
WO2009158618A2 (en) * 2008-06-26 2009-12-30 Biomune Company Unique avian reoviridae
FR2939807B1 (fr) * 2008-12-11 2010-12-17 Biomerieux Sa Nouveau reovirus isole, procedes et kits de detection
WO2011041789A1 (en) * 2009-10-02 2011-04-07 The Trustees Of Columbia University In The City Of New York Piscine reovirus immunogenic compositions
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
EA201390810A1 (ru) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
ES2822199T3 (es) * 2011-04-29 2021-04-29 Oncolytics Biotech Inc Métodos de purificación de virus usando cromatografía por permeación en gel
DK3068411T3 (da) 2013-11-15 2020-06-22 Oncolytics Biotech Inc Oncolytiske vira og forøget cancerbehandlingsregimer
US9660989B1 (en) 2014-01-31 2017-05-23 Google Inc. Internet-wide identity management widget
US11077157B2 (en) 2016-02-16 2021-08-03 Osaka University Medicinal composition for treating fibrosis
WO2019237063A1 (en) * 2018-06-07 2019-12-12 Emory University Modified reoviruses, particles, and uses in treating proliferative disorders
KR102401077B1 (ko) 2019-01-25 2022-05-24 바이로큐어 주식회사 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물
US20240041959A1 (en) * 2020-12-22 2024-02-08 Virocure, Inc. Novel modified reovirus and use thereof
WO2023048532A1 (ko) * 2021-09-24 2023-03-30 바이로큐어 주식회사 레오바이러스 기반 신규한 백신플랫폼 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
CA2428206C (en) * 2000-11-09 2005-09-27 Oncolytics Biotech Inc. Methods for the treatment of cellular proliferative disorders
AU2002220416A1 (en) * 2000-12-01 2002-06-11 University Of Ottawa Oncolytic virus
NZ527525A (en) * 2001-03-16 2005-03-24 Oncolytics Biotech Inc Extraction of infectious virus which is suitable for clinical administration to mammals
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
CA2571849A1 (en) * 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing dendritic cell having rna virus transferred thereinto
US10260049B2 (en) * 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US20100086522A1 (en) 2006-07-18 2010-04-08 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
ES2548442T3 (es) 2007-03-12 2015-10-16 Oncolytics Biotech Inc. Reovirus que tienen secuencias modificadas
CA2723587C (en) * 2008-05-27 2017-09-26 Oncolytics Biotech Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
CN103269716B (zh) * 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
EA201390810A1 (ru) * 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы

Also Published As

Publication number Publication date
KR20090125103A (ko) 2009-12-03
US10596260B2 (en) 2020-03-24
EP2132315A1 (en) 2009-12-16
IL221702A0 (en) 2012-10-31
US20140186301A1 (en) 2014-07-03
ZA200905951B (en) 2010-11-24
US11246930B2 (en) 2022-02-15
HK1132761A1 (en) 2010-03-05
MX346950B (es) 2017-04-06
US20200237917A1 (en) 2020-07-30
IL221701A0 (en) 2012-10-31
US10039827B2 (en) 2018-08-07
CA2678721C (en) 2018-02-13
JP5577103B2 (ja) 2014-08-20
US20110020288A1 (en) 2011-01-27
AU2008226291B2 (en) 2014-01-16
JP2010520758A (ja) 2010-06-17
WO2008110004A1 (en) 2008-09-18
EP2132315B1 (en) 2015-07-15
AU2008226291A1 (en) 2008-09-18
TW200904979A (en) 2009-02-01
AR066395A1 (es) 2009-08-19
EP2132315A4 (en) 2011-10-05
CN103710359A (zh) 2014-04-09
IL221700A0 (en) 2012-10-31
AU2008226291A2 (en) 2009-10-08
DK2132315T3 (en) 2015-10-19
IL200353A0 (en) 2011-08-01
SG191602A1 (en) 2013-07-31
US20090035278A2 (en) 2009-02-05
CA2678721A1 (en) 2008-09-18
EP2952583A1 (en) 2015-12-09
IL200353A (en) 2017-07-31
US20080226602A1 (en) 2008-09-18
US20180344853A1 (en) 2018-12-06
US7803385B2 (en) 2010-09-28
KR101647843B1 (ko) 2016-08-11
US8691241B2 (en) 2014-04-08
MX2009009598A (es) 2009-09-21

Similar Documents

Publication Publication Date Title
ES2548442T3 (es) Reovirus que tienen secuencias modificadas
Shamoo et al. Crystal structure of the two RNA binding domains of human hnRNP A1 at 1.75 Å resolution
Bax et al. X-ray analysis of βB2-crystallin and evolution of oligomeric lens proteins
Carlson et al. Lack of Borrelia burgdorferi DNA in synovial samples from patients with antibiotic treatment–resistant Lyme arthritis
Beall et al. A Drosophila protein homologous to the human p70 Ku autoimmune antigen interacts with the P transposable element inverted repeats.
Chu et al. Tropomyosin is the major mollusk allergen: reverse transcriptase polymerase chain reaction, expression and IgE reactivity
Fan et al. Structural basis of diverse sequence-dependent target recognition by the 8 kDa dynein light chain
Zhao et al. Structural characterization of the human respiratory syncytial virus fusion protein core
Harrison et al. Identification of the t complex–encoded cytoplasmic dynein light chain Tctex1 in inner arm I1 supports the involvement of flagellar dyneins in meiotic drive
Devarajan et al. Ankyrin binds to two distinct cytoplasmic domains of Na, K-ATPase alpha subunit.
Marino et al. Complement in urochordates: cloning and characterization of two C3-like genes in the ascidian Ciona intestinalis
Bardele Functional and phylogenetic aspects of the ciliary membrane: a comparative freeze-fracture study
Weekers et al. Sequence variations in small-subunit ribosomal RNAs of Hartmannella vermiformis and their phylogenetic implications.
Ono et al. Production and characterization of recombinant human Ku antigen
Ahne et al. Comparative sequence analyses of sixteen reptilian paramyxoviruses
CZ20001963A3 (cs) Peptidy obsahující citrulin rozeznaný sérem revmatické artritidy jako prostředky pro diagnózu a léčbu
Yoshida et al. Translocation of HSP27 and MKBP in ischemic heart
Glele‐Kakai et al. Epidemiological studies of spectrin mutations related to hereditary elliptocytosis and spectrin polymorphisms in Benin
Antao et al. MHC class I genes of the channel catfish: sequence analysis and expression
Ciszak et al. Crystal structure determination at 2.3-A resolution of human transthyretin-3', 5'-dibromo-2', 4, 4', 6-tetrahydroxyaurone complex.
Romac et al. The U1 small nuclear ribonucleoprotein (snRNP) 70K protein is transported independently of U1 snRNP particles via a nuclear localization signal in the RNA-binding domain
Chang et al. Structure–function studies on Taiwan cobra long neurotoxin homolog
Liu et al. Rapid characterization of avian reoviruses using phylogenetic analysis, reverse transcription-polymerase chain reaction and restriction enzyme fragment length polymorphism
Southgate et al. Alternative splicing of an amino-terminal PEVK-like region generates multiple isoforms of Drosophila projectin
Poyarkov et al. Phylogeography of the Siberian newt Salamandrella keyserlingii by mitochondrial DNA sequence analysis